| Date Filed | Type | Description |
| 08/18/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 9.9% stake in Kiniksa Pharmaceuticals, Ltd. |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 06/30/2023 |
SC 13D/A
| HHLR ADVISORS, LTD. reports a 8.3% stake in I-MAB |
| 06/15/2023 |
4
| HHLR ADVISORS, LTD. (10% Owner) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 611,000 shares
@ $211.4522, valued at
$129.2M
Sold 313,400 shares
@ $128.4335, valued at
$40.3M
Sold 273,728 shares
@ $207.7171, valued at
$56.9M
|
|
| 06/12/2023 |
4
| HHLR ADVISORS, LTD. (10% Owner) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Sold 1,163,825 shares
@ $218.1443, valued at
$253.9M
Sold 213,700 shares
@ $130.3523, valued at
$27.9M
Sold 328,952 shares
@ $217.0183, valued at
$71.4M
Sold 281,400 shares
@ $130.8322, valued at
$36.8M
Sold 968,812 shares
@ $213.9125, valued at
$207.2M
|
|
| 06/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/15/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 6.4% stake in Cytek Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 5.3% stake in Gossamer Bio, Inc. |
| 02/14/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 7.6% stake in Kiniksa Pharmaceuticals, Ltd. |
| 02/14/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 11.9% stake in MOGU Inc. |
| 02/14/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 15.6% stake in Bright Scholar Education Holdings Limited |
| 02/14/2023 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 19.1% stake in Yatsen Holding Ltd. |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/24/2022 |
4
| HHLR ADVISORS, LTD. (10% Owner) has filed a Form 4 on BeiGene, Ltd.|
Txns:
| Acquired 7,800 shares
@ $0 |
|
| 08/16/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
SC 13G
| HHLR ADVISORS, LTD. reports a 5.3% stake in On Holding AG |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 3.3% stake in KE Holdings Inc. |
| 02/14/2022 |
SC 13G
| HHLR ADVISORS, LTD. reports a 6.5% stake in Cytek Biosciences, Inc. |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 5.6% stake in Aligos Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a |
| 02/14/2022 |
SC 13G
| HHLR ADVISORS, LTD. reports a 5.8% stake in Agora, Inc. |
| 02/14/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 0% stake in Leap Therapeutics, Inc. |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 0% stake in Beam Therapeutics Inc. |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 0% stake in Apellis Pharmaceuticals, Inc. |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 18% stake in Yatsen Holding Ltd. |
| 02/14/2022 |
SC 13G/A
| HHLR ADVISORS, LTD. reports a 5.2% stake in Root, Inc. |
|